Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Integrating genome-wide and epigenome-wide associations for antipsychotic induced extrapyramidal side effects.

Psychopharmacology - 1 Jul 2026

Yao Kai, Thygesen Johan H, Lock Siobhan K, Pardiñas Antonio F, Pritchard Antonia L, Elbashir Israa, Lodhi Abdullah, Ahmad Zain-Ul-Abideen, O'Donovan Michael C, Owen Michael J, Walters James T R, St Clair David, Bass Nick, McQuillin Andrew

Abstract excerpt

RATIONALE: Antipsychotic medications are the first-line treatment for schizophrenia. Around 40% of people who are treated with antipsychotics could develop extrapyramidal side-effects (EPSE) including: (1) Dyskinesia, (2) Parkinsonism, (3) Akathisia, and (4) Dystonia. OBJECTIVES: This study aimed to identify genetic risk factors for EPSE presence following antipsychotic treatment. METHODS: We conducted...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents
Share to Basal Ganglia Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epigenome

Share to FGA gene

Share to Genetic Risk Score

Share to Genome-Wide Association Study

Share to Polymorphism, Single Nucleotide

Share to Schizophrenia

Source

Open in PubMed Open full text

Identifiers

PMID: 41074960
DOI: 10.1007/s00213-025-06912-w
PMCID: PMC13433426

Genes

FGA
STK32B
CNBD1
LSAMP
NAV2
NRG3
SHISA9
TMSB15B

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Integrating genome-wide and epigenome-wide associations for antipsychotic induced extrapyramidal side effects.PMID 41074960Read ↗

Integrating Genome-wide and Epigenome-wide Associations for Antipsychotic Induced Extrapyramidal Side EffectsSemantic proximity Read ↗

Genomewide association study of movement-related adverse antipsychotic effects.Semantic proximity Read ↗

A genetic dissection of antipsychotic induced movement disorders.Semantic proximity Read ↗

The genetics of antipsychotic induced tremors: a genome-wide pathway analysis on the STEP-BD SCP sample.Semantic proximity Read ↗

Pharmacogenomic and inflammatory determinants of antipsychotic-induced extrapyramidal toxicity in Egyptian patients with schizophrenia.Semantic proximity Read ↗

Improving pharmacogenetic prediction of extrapyramidal symptoms induced by antipsychoticsSemantic proximity Read ↗

Genetics of Common Antipsychotic-Induced Adverse EffectsSemantic proximity Read ↗

Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients.Semantic proximity Read ↗

Genome-wide association mapping of loci for antipsychotic-induced extrapyramidal symptoms in mice.Semantic proximity Read ↗

Pharmacogenetics of tardive dyskinesia: an updated review of the literature.Semantic proximity Read ↗

Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes.Semantic proximity Read ↗

Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.